Qlaris Bio Adds Robert Warner to Board of Directors

Published on January 29, 2026
DEDHAM, Mass.—Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing therapies for glaucoma, has announced the appointment of Robert Warner to its board of directors, effective immediately. Warner is an experienced life sciences executive and board member with a strong track record of leadership across biotechnology and health care companies, the announcement noted. His appointment comes at a key time for Qlaris, the company advised, as it continues to advance its lead development program, QLS 111, through late-stage clinical trials as a novel therapeutic agent for the treatment of glaucoma.
Continue reading on website
Other news

Eschenbach Sponsors Two Students With Vision Loss to Attend Space Camp for Interested Visually Impaired Students

January 29, 2026
DANBURY, Conn.—For the fourth consecutive year, Eschenbach Optik of America, Inc. announced it had sponsored two students with a vision impairment to attend the Space Camp for Interested Visually Impaired Students (SCIVIS). Celebrating its 35th anniversary, the camp was held from September 28 to October 2, 2025, in the U.S. Space and Rocket Center in Huntsville, Ala., and served as an educational

PRESS Eyewear Appoints Anthony Reid as European General Manager

January 29, 2026
NEW YORK—PRESS Eyewear, an independent luxury eyewear brand, has announced the appointment of Anthony Reid as its new European general manager, effective immediately. Having led international commercial strategy and brand development at a senior level, the company said Reid’s appointment supports PRESS Eyewear’s next phase of growth, with a clear focus on disciplined distribution, operational stru